Clinical Trial Awareness Is the Start of Consent.

The first advertisement, search result, physician comment, or advocacy message begins shaping the patient's decision long before a consent form appears.

The first contact already changes the decision.

FDA guidance treats direct advertising for research subjects as the beginning of informed consent and subject selection. That is a useful standard for every awareness channel, including search, social media, patient advocacy, physician referral, and condition-specific education.

A headline can frame an investigational product as hope, risk, access, or experimentation. An image can signal who belongs. A call to action can invite learning or create pressure. Outreach is therefore part of the research experience, even when the patient never reaches a site.

Visibility is necessary. It is not readiness.

Patients cannot consider an opportunity they never encounter. But impressions, clicks, and form fills do not show that the study is understood. They show only that the message reached someone and produced an action.

The next question is whether awareness created accurate expectations. Does the patient understand that the intervention is investigational? Is the purpose clear? Are basic eligibility, location, time commitment, and next steps visible? Can the patient explore without surrendering contact information or feeling pushed to enroll?

An ethical message creates relevance without certainty.

Recruitment content should explain the condition under study, the research purpose, basic eligibility, site location, and how to learn more. It should avoid implying that the intervention is proven, superior, guaranteed, or equivalent to care. Payment may be disclosed, but it should not dominate the message.

Relevance should come from the patient's condition and questions, not exaggerated benefit. Plain language, representative imagery, accessible formats, and clear investigational status help patients recognize the opportunity while preserving an honest view of uncertainty.

Measure what the first contact prepared.

Campaign performance should include more than reach and response. Teams should examine whether patients arrive with accurate expectations, whether the correct populations can find the study, where misinformation appears, and whether downstream questions reveal confusion created upstream.

A high-response message that produces low comprehension or poor site handoff is not efficient. It transfers cost and correction to the next stage. Ethical awareness performs when the patient reaches the next conversation better oriented, not merely more interested.

Sources.

1. FDA, Recruiting Study Subjects
2. FDA, Informed Consent Guidance
3. NIH, Guiding Principles for Ethical Research
4. Sood et al., Patient Attitudes and Recruitment Preferences

About the author

Rebecca Schelkun

Vice President, Patient Readiness

Rebecca is Vice President of Patient Readiness at Jumo Health. She combines public health expertise in epidemiology and biostatistics with experience across health equity, patient advocacy, pediatrics, rare disease, and clinical trial strategy. At Jumo, she turns protocol demands and lived experience into education, decision support, and expectation alignment patients can use.